No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Achilles Therapeutics Regains Nasdaq Compliance, Boosting Investor Confidence
Express News | Achilles Therapeutics PLC - Transfer Effective November 19, 2024
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Achilles Therapeutics 3Q Loss/Shr 48c >ACHL
Press Release: Achilles Therapeutics Reports Third Quarter 2024 Financial Results
European Equities Traded in the US as American Depositary Receipts Decrease Friday
Unlock the Full List